The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Hermann EinseleDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, What are the management strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity in multiple myeloma?
What are the management strategies for CRS and ICANS in MM?
Einsele discusses the management of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients treated with common immunotherapies such as chimeric antigen receptor T cells and bispecific antibodies. He then outlines the incidence and risk factors associated with immune-mediated toxicities from these immunotherapies. Finally, Einsele concludes by exploring several therapeutic strategies, including the use of bridging therapies, prophylactic steroids, and supportive care.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content